AAM Statement on 2020 Election
WASHINGTON, DC (November 11, 2020) — The Association for Accessible Medicines looks forward to working with the incoming Biden-Harris administration to achieve our shared goal of increasing access to safe, effective and affordable generic and biosimilar prescription medicines for all Americans.
While utilization of generic drugs saved the U.S. health care system $313 billion last year alone, there is more to be done to ensure generic and biosimilar manufacturers can bring new therapies to market in a timely manner saving patients, job creators and taxpayers additional billions of dollars. Our members produce critical medicines that are the bridge to a COVID-19 vaccine, and together with them, I look forward to working with the Biden administration and the 117th Congress to improve the lives of patients across the country.
Attribution: Dan Leonard, President and CEO, AAM
MEDIA CONTACT:
Rachel Schwartz
202.249.7147
About the Biosimilars Council
The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available on our about page.
About AAM
AAM is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers and distributors of finished generic pharmaceuticals and biosimilars, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 20 percent of total drug spending.
